Catalyst ligands

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2304-30-5,Tetrabutylphosphonium chloride,as a common compound, the synthetic route is as follows.

A stirred solution of sodium 2,2-dimethyl-N,N-dichlorotaurine (35 g, 143 mmol) in 175 mL of water was treated with a solution of tetrabutylphosphonium chloride (38 g, 129 mmol) in 175 mL of water. The resulting suspension was stirred 10 min then 400 mL of ethyl acetate was added and the mixture was stirred vigorously. After separation of the layers, the aqueous layer was extracted with 2¡Á200 mL of ethyl acetate. The combined organic layers were dried over sodium sulfate and filtered. The sodium sulfate pad was washed with 2¡Á100 mL of ethyl acetate. The filtrate was concentrated to dryness and placed under high vacuum overnight (0.4 torr)to constant weight which provided 2,2-dimethyl-N,N-dichlorotaurine tetrabutylphosphonium (59.9 g, 96.6%) as a white solid, mp 118-120 C. 1H NMR (CDCL3) 3.34 (s, 2H); 2.33 (q, 8H); 1.65 (s, 6H); 1.54 (m, 16H); 0.99 (t, 12H)., 2304-30-5

The synthetic route of 2304-30-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ALCON RESEARCH, LTD.; US2009/197838; (2009); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Di-tert-butyl dicarbonate (Boc2O, 5.1 g, 23.2 mmol) in anhydrous trichloromethane (30 mL) was added dropwise to a stirred solution of TACN (2.0 g, 15.5 mmol) and triethylamine (4.7 mL, 3.1 g, 31.0 mmol) in anhydrous trichloromethane (100 mL). The resulting reaction mixture was stirred for 24 h at room temperature. Excess triethylamine was removed by washing the reaction mixture with water (3 ¡Á 50 mL) and brine (2 ¡Á 50 mL). The organic layer was collected and dried over anhydrous magnesium sulfate and then filtered. The solvent was evaporated under reduced pressure to give the crude products which were purified by chromatography over silica (EtOAc(EA)/Petroleum ether(PE), 1 : 1, v/v) as colorless oil 2Boc-TACN (1) (Rf = 0.5, EA).

4730-54-5, The synthetic route of 4730-54-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Wang, Bing; Yi, Wen-Jing; Zhang, Ji; Zhang, Qin-Fang; Xun, Miao-Miao; Yu, Xiao-Qi; Bioorganic and Medicinal Chemistry Letters; vol. 24; 7; (2014); p. 1771 – 1775;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.134030-21-0,N1,N2-Dimesitylethane-1,2-diamine,as a common compound, the synthetic route is as follows.

Preparation of 1,3-dimesityl-4,5-dihydro-imidazolium tetrafluoroborate A round bottom flask was charged with 1,2-dimesityl ethylene diamine (3.8 g, 12.8 mmol), triethyl orthoformate (15 mL) and ammonium tetrafluoroborate (1.35 g, 12.8 mmol). The reaction mixture was stirred at 120 C. for 4 hours at which time TLC indicated complete conversion. Volatiles were removed in vacuo and the product was used as prepared or it could be purified further by recrystallization from ethanol/hexanes.

134030-21-0, As the paragraph descriping shows that 134030-21-0 is playing an increasingly important role.

Reference£º
Patent; CALIFORNIA INSTITUTE OF TECHNOLOGY; GRUBBS, Robert H.; SCHOLL, Matthias; (16 pag.)US2016/237101; (2016); A9;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4730-54-5,1,4,7-Triazacyclononane,as a common compound, the synthetic route is as follows.

General procedure: To a solution of 1,4,7-triazacyclononane (2 mmol) in distilled ethanol (50 mL) containing molecular sieve was added 1 equiv of aldehyde. The reaction mixture was stirred at room temperature. The solution was filtered and the filtrate was evaporated under reduced pressure to yield the aminal adduct., 4730-54-5

As the paragraph descriping shows that 4730-54-5 is playing an increasingly important role.

Reference£º
Article; Roger, Melissa; Patinec, Veronique; Bourgeois, Martine; Tripier, Raphael; Triki, Smail; Handel, Henri; Tetrahedron; vol. 68; 27-28; (2012); p. 5637 – 5643;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

66127-01-3,66127-01-3, 3-Bromo-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Compound 1: A mixture of 2-Br-phen (0.80 g, 3.10 mmol), 2-thiophenylboronic acid (0.42 g, 3.28 mmol), Pd(PPh3)4 (0.12 g, 0.10 mmol) and Cs2CO3 (3.03 g, 9.30 mmol) was dissolved in a mixture of dioxane (40 mL) and H2O (8 mL), placed into a degassed three-necked flask and refluxed under an argon atmosphere for 8 h. After the solution was cooled to room temperature, the solvent was removed under reduced pressure and the residue was dissolved in CHCl3 (50 mL), washed with excess water, and dried with anhydrous Na2SO4. The desired compound 1 was finally separated as light yellow solid by silica gel column chromatography using CHCl3/petroleum ether (v:v 5:1) as the eluent in a yield of 0.71 g (87%). Similarly, compounds 3 and L1 were obtained via the same synthetic method in the yields of 42 and 77%, respectively. Compound 3: 1H NMR (300 MHz, CDCl3) delta: 9.45 (d, 1H, J=2.3 Hz, phen), 9.20 (dd, 1H, J=4.4, 1.7 Hz, phen), 8.35 (d, 1H, J=2.3 Hz, phen), 8.25 (dd, 1H, J=8.1, 1.7 Hz, phen), 7.79 (s, 2H, phen), 7.64-7.57 (m, 2H, phenthienyl), 7.45 (dd, 1H, J=5.1, 1.1 Hz, thienyl), 7.20-7.18 (m, 1H, thienyl).

The synthetic route of 66127-01-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Peng, Yu-Xin; Xu, Dan; Wang, Na; Tao, Tao; Hu, Bin; Huang, Wei; Tetrahedron; vol. 72; 24; (2016); p. 3443 – 3453;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

54258-41-2,54258-41-2, 1,10-Phenanthrolin-5-amine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Both compounds were synthesized in the same way. A mixture ofthe appropriate aldehyde [thiophene-2,5-dicarbaldehyde (283 mg,2.02 mmol), furan-2,5-dicarbaldehyde (316 mg, 2.55 mmol)] and5-amino-1,10-phenanthroline [(1091 mg, 5.59 mmol) withthiophene-2,5-dicarbaldehyde, (1458 mg, 7.48 mmol) with furan-2,5-dicarbaldehyde] was refluxed in EtOH (50 mL) containing acatalytic amount of acetic acid for 12 h, giving a suspension. Thereaction mixture was filtered hot, and the solid was washed withEtOH to afford the desired product as a yellow solid.

As the paragraph descriping shows that 54258-41-2 is playing an increasingly important role.

Reference£º
Article; Cheng, Feixiang; He, Chixian; Yu, Shiwen; Yin, Hongju; Inorganica Chimica Acta; vol. 462; (2017); p. 43 – 49;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4568-71-2,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4568-71-2,3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride,as a common compound, the synthetic route is as follows.

1-(3-Methoxy-4-hydroxyethoxy-5-iodophenyl)-4-(3,4,5-trimethoxyphenyl)-1,4-butanedione (compound 105) 3,4,5-Trimethoxyphenylvinylketone (4.8 g, 21.6 mmol), 3-methoxy-4-hydroxyethoxy-5-iodobenzaldehyde (5.7 g. 17.8 mmol), and 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (1.9 g, 7.0 mmol) were stirred in triethylamine (20 mL) at 60¡ã C. for 16 hours. The reaction mixture was then acidified with 10percent HCl, and extracted with dichloromethane. The organic layer was dried over MgSO4, filtered and evaporated in vacuo. The product was purified in column chromatography (silica, 1:1 hexane/ethyl acetate) as a solid (9.7 g, 51percent). 1 H NMR (CDCl3) delta3.41 (m, 4H); 3.90 (m, 2H); 3.92 (s, 3H); 3.93 (s, 9H); 4.26 (t, 2H); 7.29 (s, 2H); 7.57 (d, 1H); 8.08 (d, 1H).

4568-71-2 3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride 2833352, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Cytomed, Inc.; US5463083; (1995); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

128143-89-5, 4′-Chloro-2,2′:6′,2”-terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The syntheses of ligands were carried out by literature procedures [48-50]. To a suspensionof KOH in dry DMSO at 50 C, ethylene glycol and its respective polymer (n = 2, 3, or 4)in excess were added. After stirring for 30 min, 4?-chloro-2,2? : 6?,2??-terpyridine was addedand the reaction mixture was stirred for 20 h at this temperature. Upon cooling to roomtemperature, the reacting mixture was treated with deionised water and filtered. The crudeproduct was extracted from the filtrate in dichloromethane (3 ¡Á 30 mL), dried overanhydrous magnesium sulfate, and then the solvent was removed., 128143-89-5

As the paragraph descriping shows that 128143-89-5 is playing an increasingly important role.

Reference£º
Article; Shaira; Jaganyi; Journal of Coordination Chemistry; vol. 67; 17; (2014); p. 2843 – 2857;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

103946-54-9, 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

87 mg of 4′-methyl- (2,2′-bipyridine) -4-carboxylic acid was dissolved in anhydrous THF and dissolved in anhydrous DMF. Under ice bath conditions, HOBt 55mg and DCC 100mg were completely dissolved and activated for 30min.The prepared HCl ¡¤ Arg (Tos) -Gly-Asp (OBzl) -Ser-OBzl 312 mg was added and the pH adjusted to 8.0-9.0 with DMM. The reaction was stirred at room temperature for 14h,The reaction was monitored by TLC plate. 328 mg (89% of product) of a pink solid powder was obtained., 103946-54-9

The synthetic route of 103946-54-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Capital University of Medical Sciences; Cui Chunying; Lin Na; (23 pag.)CN107320736; (2017); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5,62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

D-Prolinamide (42.8 mg, 375 muiotaetaomicron) and N,N-diisopropylethylamine (65 mu, 380 mumol) were added to a solution of 2-[3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5- dihydro-lH-l,2,4-triazol-l-yl}methyl)-lH-l,2,4-triazol-l-yl]benzoyl chloride (Example 58A, 79.1 mg, 150 muiotaetaomicron) in tetrahydrofuran (2.3 ml). This reaction mixture was stirred for 1 h at room temperature. The crude product was purified by preparative HPLC (Method 4). Lyophihsation of the product containing fractions afforded 53.9 mg (57 % of th.) of the title compound. LC-MS (Method 2): Rt = 1.53 min; MS (ESIpos): m/z = 605 [M+H]+ -NMR (400 MHz, DMSO-d6) delta [ppm]: -0.215 (1.05), -0.008 (3.93), 0.008 (3.02), 0.716 (3.19), 1.701 (2.80), 1.716 (2.72), 1.742 (2.33), 1.759 (3.07), 1.776 (3.57), 1.787 (3.15), 1.798 (2.94), 1.812 (1.93), 2.053 (1.59), 2.073 (1.94), 2.709 (0.57), 3.205 (1.74), 3.231 (1.37), 3.247 (2.09), 3.287 (4.72), 3.373 (0.82), 3.441 (1.05), 3.816 (1.83), 3.824 (1.18), 3.840 (2.10), 3.852 (2.94), 3.860 (1.87), 3.877 (2.98), 3.884 (2.00), 3.974 (4.06), 3.982 (4.47), 4.010 (2.84), 4.019 (2.68), 4.217 (1.80), 4.229 (1.82), 4.309 (2.20), 5.021 (1.30), 5.061 (14.55), 5.069 (10.76), 5.109 (1.19), 6.913 (3.15), 6.928 (5.00), 6.958 (4.94), 6.973 (4.86), 7.064 (3.77), 7.297 (2.31), 7.342 (3.89), 7.411 (1.12), 7.472 (1.37), 7.492 (2.44), 7.509 (1.27), 7.539 (1.39), 7.556 (3.82), 7.577 (3.93), 7.601 (12.46), 7.614 (6.91), 7.617 (8.60), 7.622 (16.00), 7.629 (8.66), 7.635 (11.09), 7.648 (3.33), 7.676 (3.24), 7.696 (2.26), 7.723 (5.02), 7.745 (10.67), 7.752 (12.89), 7.767 (6.68), 7.773 (9.27), 8.933 (10.76).

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; COLLIN-KROePELIN, Marie-Pierre; KOLKHOF, Peter; NEUBAUER, Thomas; FUeRSTNER, Chantal; POOK, Elisabeth; WITTWER, Matthias, Beat; LUSTIG, Klemens; TINEL, Hanna; LINDNER, Niels; SCHIRMER, Heiko; (449 pag.)WO2019/81307; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI